10 Most Popular Stocks Among Hedge Funds – Q3
After each quarter, hedge funds and other major investors disclose many of their long equity positions with the U.S. Securities and Exchange Commission...
Posts Tagged ‘Jeffrey Ubben ValueAct Capital Management’
Valeant Pharmaceuticals Intl Inc (VRX), Motorola Solutions Inc (MSI): Is An Activist-Mimicking Mutual Fund A Smart Investment?
At Insider Monkey, we use a number of techniques to track investment activity by hedge funds and other notable investors. Our research has shown that...
This Metric Says You Are Smart to Buy Gardner Denver, Inc. (NYSE:GDI)
Is Gardner Denver, Inc. (NYSE:GDI) a buy right now? Prominent investors are in an optimistic mood. The number of bullish hedge fund bets rose by 23 lately...
Multiple Insiders Have Bought Valeant and These Healthcare Stocks
Stocks bought by insiders tend to outperform the market, and the effect is particularly strong when multiple insiders are buying (learn more about studies...
Is Halliburton a Good Stock to Buy After Earnings?
Halliburton Company (NYSE:HAL) reported its results for the fourth quarter of 2012 on January 25th. Earnings were down from the fourth quarter of 2012...
ValueAct’s Jeffrey Ubben’s Top Stock Picks Include Adobe Systems
Jeffrey Ubben is an activist investor, but a patient one; rather than agitate for immediate change and use the media to increase pressure on management...
State Street, General Dynamics, and More: Billionaire Thomas Steyer’s Cheap Stock Picks
Farallon Capital Management is one of the largest hedge funds in the world, with over $20 billion in assets under management at the beginning of 2012....
Jeff Ubben’s Wall Street Journal Op-Ed
By Jeff Ubben Corporate America is stuck in a rut, and it is holding back economic growth. Despite record-low financing costs, capital-expenditure plans...
Is Adobe a Good Stock to Buy?
Adobe Systems Incorporated (NASDAQ:ADBE) is most widely known for its Adobe Reader software, but the company’s other offerings have been built into...
Criterion Capital’s Top Stock Picks
Criterion Capital is a long/short investment fund that focuses on technology, media, and telecommunications investments. As of the end of June, over 75...
Top Stock Picks by Long-Term Value Hedge Fund
Jeffrey Ubben founded ValueAct Capital and, since 2000, has served as its CEO and CIO. Prior to founding and managing his own fund, Ubben was a managing...
Why is Blum Capital Downsizing its Position in This Real Estate Company?
In a recent filing, Richard Blum and Blum Capital Partners downsized its long-time stake in the commercial real estate services firm CBRE Group Inc. (...
Jeffrey Ubben’s Top Stock Picks
Jeffrey Ubben is the founder of ValueAct Capital and he has served as the Chief Executive Officer and Chief Investment Officer of the company since 2000...
Is $NYT a Good Deal or is a Competitor a Better? $GCI $MNI $WPO
The New York Times Company (NYT) publishes the New York Times, the popular national and regional paper. Jeffrey Ubben’s Valueact Capital, Ken Griffin...
Hedge funds Lose After Adobe $ADBE Shares Fall Nearly 11%
Shares of Adobe (ADBE) fell Wednesday after the company announced that it would no longer be focusing on making Flash for mobile browsers. Specifically...
ValueAct Capital and Jeffrey Ubben’s Portfolio
Valueact Capital is founded by Jeffrey Ubben, 49 years old, in 2000. Prior to founding Valueact Jeffrey Ubben served as a managing partner at Blum Capital...
25 Best Performing Hedge Funds in This Market Turmoil
Insider Monkey tracks more than 300 hedge funds and a few mutual funds with stellar reputation. We believe investors can beat the index funds by imitating...
25 Best Hedge Funds of Q2 2011
Insider Monkey tracks 300+ hedge funds and several other prominent investors. We believe investors can beat the index funds by imitating best hedge funds...
These Hedge Funds Lost a Bundle on La-Z-Boy and Adobe $LZB $ADBE
La-Z-Boy (LZB) shares declined nearly 12% today after Brian Sozzi -an analyst with Wall Street Strategies- cut his recommendation to hold. On the other...
Jeffrey Ubben, James Mitarotonda, Brevan Howard
Ubben’s Latest Move (Marketwatch) Valeant Pharmaceuticals International’s $5.7 billion bid for drug maker Cephalon Inc. is the latest in an acquisition...
